Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cystine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystine SCHEMBL258646 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8158993 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL1072437 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL375413 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL258647 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL375415 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8158997 | 1.00 | ALOX15 (0.48) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL1818813 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL8087124 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 | |
| Cystine SCHEMBL21409473 | 0.97 | ALOX15 (0.47) | ALOX15ALDH1A1ARG1ARG2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121379932-B | Culture medium for high-density serum-free suspension culture of BHK-21 cells and application thereof | Zhongsheng tianxinhe (Wuxi) Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122081234-A | Low-serum MSB1 suspension medium and chicken infectious anemia virus inactivated vaccine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12616948-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2026-05-05 | — | — | US | claimed |
| US-12508565-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2025-12-30 | — | — | US | claimed |
| EP-4633791-A1 | PROTEIN-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-10-22 | — | — | EP | claimed |
| US-20250281371-A1 | PLANT PROTEIN-BASED MICROCAPSULES | FIRMENICH SA (CH) | 2025-09-11 | — | — | US | claimed |
| CN-120115098-A | Method for producing polyamide microcapsules | 弗门尼舍有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119662528-A | In-vitro suspension culture medium and preparation method thereof | 北京阿尔法拜欧生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-101386837-A | Zooblast cultivation method | BEIJING TIANXINHE BIOLOG TECHN (CN) | 2009-03-18 | — | — | CN | claimed |
| CN-101381702-A | Cell culture medium without animal component | JILIN SAIDA BIOTECHNOLOGY CO L (CN) | 2009-03-11 | — | — | CN | claimed |
| CN-101195817-A | Hybrid tumor cell amplification culture medium and uses thereof | TIANJIN BAINUOKE MEDICINE BIOT (CN) | 2008-06-11 | — | — | CN | claimed |
| EP-1204402-B1 | SULFUR ADSORBENT FOR REDUCING ONION OR GARLIC BREATH ODOR | PQ HOLDING INC (US) | 2004-11-24 | — | — | EP | claimed |
| US-6403642-B1 | CYSTINE-COPPER COMPLEX THAT ABSORBS THIOL ODORS | PQ HOLDING, INC. | 2002-06-11 | — | — | US | claimed |
| EP-1204402-A2 | SULFUR ADSORBENT FOR REDUCING ONION OR GARLIC BREATH ODOR | PQ Holding, Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| EP-1142925-A1 | PROCESSES FOR PRODUCING WATER-ABSORBING RESIN | Mitsui Chemicals, Inc. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2001012136-A2 | SULFUR ADSORBENT FOR REDUCING ONION OR GARLIC BREATH ODOR | PQ HOLDING, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| EP-1051971-A1 | Patch and method for transdermal delivery of bupropion base | Pierce Management, L.L.P. (US) | 2000-11-15 | — | — | EP | claimed |
| CN-1232091-A | Electrolytic bath for pollution-free electrolytic synthesis of L-cysteine hydrochloride and glyoxalic acid | UNIV HUAZHONG (CN) | 1999-10-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508565-B2 | Polyamide microcapsules | PHGDH, GLUL, PCCA | PTGS1 2960/4885GRIN2D 303/4885GRIN3B 2000/4885 |
| US-20250281371-A1 | PLANT PROTEIN-BASED MICROCAPSULES | CUTA, PHLPP2, PHLPP1 | PTGS1 4109/4885GRIN2D 4512/4885GRIN3B 4549/4885 |
| US-12616948-B2 | Polyamide microcapsules | HDHD5, DDC, USP39 | PTGS1 4188/4885GRIN2D 2845/4885GRIN3B 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.